FDA Brief

Warning letters Drugs

FDA warning letter to

Chromatography Institute of America dba Compounder’s International Analytical Laboratory

High riskIssued Aug 20, 2025Posted Sep 2, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Chromatography Institute of America, a Colorado contract drug testing lab, that sterility testing and quality controls violated current good manufacturing practice.

What happened

FDA inspected the contract testing laboratory from February 24 to March 5, 2025. The agency found inadequate laboratory controls for microbiological testing, inadequate investigations of failed sterility tests, and insufficient Quality Unit oversight. The letter also says the firm's responses were inadequate and raises concerns about the validity and integrity of data provided to 503B outsourcing facilities.

What FDA found

  1. The lab lacked adequate controls for microbiological testing, including no growth promotion testing on a media lot before use, no appropriate negative controls, and sterility retesting on only part of the original sample contrary to USP <71>, the standard for sterility testing.

    USP <71>; FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  2. The lab's investigations of nine 2024 sterility test failures were inadequate because the stated root cause of technician error and environmental contamination was not supported by environmental monitoring data, and passing retests were recorded.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  3. The quality unit, the group responsible for quality oversight, did not adequately oversee contract testing, including computer access controls, document control, and review of an uncontrolled sample-preparation document.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  4. The firm did not operate an effective quality system under current good manufacturing practice.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)

What FDA wants

FDA tells the company to respond in writing within 15 working days with what it has done to correct the violations and prevent recurrence. It also asks the firm to clarify whether it has ceased operations and to notify FDA before resuming drug testing.

Who should pay attention

  • 503B outsourcing facilities that relied on its sterility test results
  • drug manufacturers and compounders using its contract testing services
  • human and animal health companies whose products were tested there

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. NexCell Scientific Inc

    NexCell Scientific markets an unapproved, unlicensed umbilical cord blood cell product with serious manufacturing violations.

    High risk
  3. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  4. R3 Medical Companies

    FDA cites R3 Medical affiliates for selling unapproved umbilical cord and exosome biologics without licenses and with serious manufacturing violations.

    High risk